Paper42014686
A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.
Liu H and 10 others. Nat Commun, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial. Papers, record 42014686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42014686
- Disease
- type 2 diabetes mellitus613 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benzhydryl Compounds | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Glucosides | Major topic |
| Hypoglycemic Agents | Major topic |
| Obesity | Major topic |
| Thiophenes | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Area Under Curve | |
| Drug Interactions | |
| Sodium-Glucose Transporter 2 Inhibitors | |
| Pyrazoles |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| INV-007625, America | Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) | PubMed | ||
| CFH 2022- 2Z- 40917 | Capital Foundation of Medical Development (Capital Foundation of Medical Development of China) | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03790787 | Drug Interaction Study Between Dorzagliatin and Empagliflozin | Derived from the trial | Yes |
Source ClinicalTrials.gov
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29946963 | Empagliflozin: A Review in Type 2 Diabetes. | Drugs | 2018 | https://conductscience.org/library/papers/29946963 | PubMed |
| 2 | 37385967 | Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study. | Diabetes Obes Metab | 2023 | https://conductscience.org/library/papers/37385967 | PubMed |
| 3 | 37356446 | Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. | Lancet | 2023 | https://conductscience.org/library/papers/37356446 | PubMed |
| 4 | 24463448 | Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | J Clin Invest | 2014 | https://conductscience.org/library/papers/24463448 | PubMed |
| 5 | 34027215 | Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state. | Arch Med Sci Atheroscler Dis | 2021 | https://conductscience.org/library/papers/34027215 | PubMed |
| 6 | 38394489 | Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials. | Medicine (Baltimore) | 2024 | https://conductscience.org/library/papers/38394489 | PubMed |
| 7 | 34610719 | Assessment of Insulin Secretion and Insulin Resistance in Human. | Diabetes Metab J | 2021 | https://conductscience.org/library/papers/34610719 | PubMed |
| 8 | 33398164 | Mechanisms controlling pancreatic islet cell function in insulin secretion. | Nat Rev Mol Cell Biol | 2021 | https://conductscience.org/library/papers/33398164 | PubMed |
| 9 | 28862799 | Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. | Diabetes Obes Metab | 2018 | https://conductscience.org/library/papers/28862799 | PubMed |
| 10 | 35551294 | Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35551294 | PubMed |
| 11 | 11147781 | Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. | Diabetes | 2001 | https://conductscience.org/library/papers/11147781 | PubMed |
| 12 | 38078590 | 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. | Diabetes Care | 2024 | https://conductscience.org/library/papers/38078590 | PubMed |
| 13 | 32035116 | Progression of insulin resistance: A link between risk factors and the incidence of diabetes. | Diabetes Res Clin Pract | 2020 | https://conductscience.org/library/papers/32035116 | PubMed |
| 14 | 37622663 | 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | Eur Heart J | 2023 | https://conductscience.org/library/papers/37622663 | PubMed |
| 15 | 24651807 | The oral minimal model method. | Diabetes | 2014 | https://conductscience.org/library/papers/24651807 | PubMed |
| 16 | 30191186 | User's guide to correlation coefficients. | Turk J Emerg Med | 2018 | https://conductscience.org/library/papers/30191186 | PubMed |
| 17 | 33822469 | Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. | Diabetes Obes Metab | 2021 | https://conductscience.org/library/papers/33822469 | PubMed |
| 18 | 31424428 | β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. | J Clin Invest | 2019 | https://conductscience.org/library/papers/31424428 | PubMed |
| 19 | 25554070 | Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. | Diabetes Metab | 2014 | https://conductscience.org/library/papers/25554070 | PubMed |
| 20 | 25274537 | Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. | Drugs | 2014 | https://conductscience.org/library/papers/25274537 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GCK | 2645 | PubTator's text mining | https://conductscience.org/library/genes/2645 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| EMPAGLIFLOZIN | CHEMBL2107830 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2107830 | ChEMBL |
| DORZAGLIATIN | CHEMBL4297508 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4297508 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Cited by
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42014686
GET https://conductscience.org/api/papers/v1/42014686/references?page=2